Binding molecules specific for HER3 and uses thereof

Patent metadata

Field	Value
Publication number	US-11305012-B2
Application number	US-201415023858-A
Country	US
Kind code	B2
Filing date	Sep 23, 2014
Priority date	Sep 24, 2013
Publication date	Apr 19, 2022
Grant date	Apr 19, 2022

Abstract

Provided herein are antibodies and antigen binding fragments thereof that bind the extracellular domain of the HER3 receptor and inhibit various HER3 receptor related functions via ligand-dependent and/or ligand-independent mechanisms. Also provided are compositions with increased half-life, as well as compositions and methods for diagnosing and treating diseases associated with HER3 mediated signal transduction.

First claim

What is claimed is:

1. A method of resensitizing a HER3-expressing tumor characterized by unregulated cell growth or HER3-expressing tumor cell characterized by unregulated cell growth in a subject to a HER targeted therapy, comprising a) administering to the subject a therapeutically effective amount of an antibody or antigen binding fragment thereof which specifically binds to an epitope within the extracellular domain of HER3, wherein the tumor or tumor cell had previously acquired resistance to the HER targeted therapy following treatment with the HER targeted therapy, wherein the HER targeted therapy is an EGFR targeted therapy, and wherein the antibody or antigen binding fragment thereof is a monoclonal antibody or antigen binding fragment thereof that comprises
(A) an antibody VL, wherein the VL comprises the amino acid sequence:
[FW 1 ]X 1 GSX 2 SNIGLNYVS(SEQ ID NO: 49)[FW 2 ]RNNQRPS(SEQ ID NO: 50)[FW 3 ]AAWDDX 3 X 4 X 5 GEX 6 (SEQ ID NO: 51)[FW 4 ]
wherein [FW 1 ], [FW 2 ], [FW 3 ] and [FW 4 ] represent VL framework regions, and wherein
(a) X 1 represents amino acid residues Arginine (R) or Serine (S),
(b) X 2 represents amino acid residues Serine (S) or Leucine (L),
(c) X 3 represents amino acid residues Serine (S) or Glycine (G),
(d) X 4 represents amino acid residues Leucine (L) or Proline (P),
(e) X 5 represents amino acid residues Arginine (R), Isoleucine (I), Proline (P) or Serine (S), and
(f) X 6 represents amino acid residues Valine (V) or Alanine (A), and

(B) an antibody VH, wherein the VH comprises the amino acid sequence:
[FW 5 ]YYYMQ(SEQ ID NO: 52)[FW 6 ]X 7 IGSSGGVTNYADSVKG(SEQ ID NO: 53)[FW 7 ]VGLGDAFDI(SEQ ID NO: 54)[FW8] wherein [FW 5 ], [FW 6 ], [FW 7 ] and [FW 8 ] represent VH framework regions, and wherein X 7 represents amino acid residues Tyrosine (Y), Isoleucine (I) or Valine (V); and b) simultaneously administering to the subject a therapeutically effective amount of the HER targeted therapy.

2. The method of claim 1 , wherein the antibody or antigen binding fragment thereof is administered for a first period of time and a second period of time, wherein there is a period of rest between the first period of time and the second period of time, wherein the antibody or antigen binding fragment thereof is not administered to the subject during the period of rest.

3. The method of claim 2 , wherein the HER targeted therapy is administered during the first period of time and the second period of time, and wherein the HER targeted therapy is not administered to the subject during the period of rest.

4. The method of claim 1 , wherein the EGFR targeted therapy is cetuximab.

5. The method of claim 1 , wherein the tumor or tumor cell is a lung cancer tumor or tumor cell, colorectal cancer tumor or tumor cell, or head and neck cancer tumor or tumor cell.

6. The method of claim 1 , wherein the antibody or antigen binding fragment comprises a VL comprising SEQ ID NO: 3 and a VH comprising SEQ ID NO: 2.

7. The method of claim 6 , wherein the antibody or antigen binding fragment comprises a heavy chain constant region or fragment thereof.

8. The method of claim 7 , wherein the heavy chain constant region or fragment thereof is an IgG constant region.

9. The method of claim 8 , wherein the IgG constant region is an IgG1 constant region.

10. The method of claim 6 , wherein the antibody or antigen binding fragment comprises a light chain constant region selected from the group consisting of a human kappa constant region and a human lambda constant region.

11. The method of claim 8 , wherein the IgG constant region comprises one or more amino acid substitutions relative to a wild-type IgG constant region wherein the modified IgG has an increased half-life compared to the half-life of an IgG having the wild-type IgG constant region.

12. The method of claim 8 , wherein the IgG constant region is a human IgG constant region that comprises amino acid substitutions relative to a wild-type human IgG constant region at positions 252, 254, and 256, wherein
(a) the amino acid at position 252 is substituted with Tyrosine (Y),
(b) the amino acid at position 254 is substituted with Threonine (T), and
(c) the amino acid at position 256 is substituted with Glutamic acid (E),
wherein the numbering is according to the EU index as set forth in Kabat.

13. The method of claim 1 , wherein the antibody is a fully human antibody, a humanized antibody, a chimeric antibody, a monoclonal antibody, a recombinant antibody, a multispecific antibody, or an antigen-binding fragment thereof.

14. The method of claim 1 , which antigen binding fragment is a Fv, Fab, F(ab′)2, Fab′, dsFv, scFv, and sc(Fv)2.

Assignees

• Medimmune Llc

Inventors

• Chowdhury Partha S
• Tice David
• Xiao Zhan
• Steiner Philipp
• Kinneer Krista
• Rebelatto Marlon
• Pierce Andrew

Classifications

• A61K39/39591 Primary

  Stabilisation, fragmentation · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K2317/73

  Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation · CPC title

• C07K16/32

  against translation products of oncogenes · CPC title

• A61K47/6849

  the antibody targeting a receptor, a cell surface antigen or a cell surface determinant · CPC title